The U.S. Food and Drug Administration (FDA) has given Pluristem Therapeutics, a leading developer of placenta-based cell therapy products, the go-ahead to move forward with its innovative treatment approach for hematopoietic disorders. Pluristem was given permission to begin its Phase I trial of PLX-R18 cells to treat incomplete hematopoietic recovery...
Continue Reading >>










